glp-1 microdosing for menopause Why GLP-1s Are a Game Changer Menopausal Weight Gain: Shamsah Amersi, MD: OB-GYNs GLP-1 Microdosing for Perimenopause: Benefits

In the absence of safety data, most clinicians advise that pregnant or breastfeeding individuals avoid this compounded preparation unless the anticipated benefit clearly outweighs theoretical fetal or neonatal risks

E., Stoddard, J., Swindle, S

While GLP 1 medications have gained attention for their role in weight loss, a quieter and more sustainable conversation is emerging around microdosing and its long term benefits for women

The crude prevalence rate of PD has been reported to range from 15 per 100,000 to 12,500 per 100,000, and the incidence of PD from 15 per 100,000 to 328 per 100,000, with the disease being less common in Asian countries

At the American Diabetes Association's Scientific Sessions, Mass General Brigham researcher Vanita Aroda, MD, presented results from SOLSTICE, a phase 2b randomized, placebo-controlled clinical trial evaluating the oral GLP-1 receptor agonist elecoglipron